Hikma acquires Roxane Laboratories
Hikma acquires Roxane Laboratories, transforming its position in the US generics market
Acquisition enhances scale and will create platform for sustainable long-term growth
Expected to be accretive in 2016 and very strongly accretive thereafter
Hikma Pharmaceuticals PLC, today announces that it has agreed to acquire Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. (together, “Roxane”), from Boehringer Ingelheim (“Boehringer”). Roxane is a well-established US specialty generics company with a highly differentiated product portfolio and best-in-class R&D capabilities.